- Home
- NCL vs SABS Comparison
NCL vs SABS Comparison
Compare NCL & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCL
- SABS
- Stock Information
- Founded
- NCL 2013
- SABS 2014
- Country
- NCL United States
- SABS United States
- Employees
- NCL N/A
- SABS N/A
- Industry
- NCL
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- NCL
- SABS Health Care
- Exchange
- NCL Nasdaq
- SABS Nasdaq
- Market Cap
- NCL 15.1M
- SABS 15.8M
- IPO Year
- NCL 2023
- SABS N/A
- Fundamental
- Price
- NCL $0.15
- SABS $2.58
- Analyst Decision
- NCL
- SABS Strong Buy
- Analyst Count
- NCL 0
- SABS 4
- Target Price
- NCL N/A
- SABS $9.50
- AVG Volume (30 Days)
- NCL 1.9M
- SABS 103.0K
- Earning Date
- NCL 08-19-2025
- SABS 11-05-2025
- Dividend Yield
- NCL N/A
- SABS N/A
- EPS Growth
- NCL N/A
- SABS N/A
- EPS
- NCL N/A
- SABS N/A
- Revenue
- NCL $12,009,378.00
- SABS $114,698.00
- Revenue This Year
- NCL N/A
- SABS N/A
- Revenue Next Year
- NCL N/A
- SABS N/A
- P/E Ratio
- NCL N/A
- SABS N/A
- Revenue Growth
- NCL N/A
- SABS N/A
- 52 Week Low
- NCL $0.13
- SABS $1.00
- 52 Week High
- NCL $1.52
- SABS $6.60
- Technical
- Relative Strength Index (RSI)
- NCL 49.21
- SABS 67.26
- Support Level
- NCL $0.14
- SABS $2.05
- Resistance Level
- NCL $0.17
- SABS $2.18
- Average True Range (ATR)
- NCL 0.01
- SABS 0.13
- MACD
- NCL 0.00
- SABS 0.03
- Stochastic Oscillator
- NCL 58.48
- SABS 91.67
About NCL Northann Corp.
Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. It offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, mainly through its sales network in North America and Europe.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.